Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
|
|
Integrated Regional Information Networks - December 14, 2004
JOHANNESBURG (PLUSNEWS) - South African drug firm Aspen Pharmacare has received the go-ahead from the US Food and Drug Administration (FDA) to produce and supply generic anti-AIDS drugs.
Aspen CEO Stephen Saad said in a statement that further FDA inspections of his company's oral solid dosage facility in Port Elizabeth were expected in the next few months.
FDA approval is required before manufacturers are allowed to supply generic anti-AIDS medication to the US President's Emergency Plan for AIDS Relief (PEPFAR), a five-year $15 billion initiative to tackle the disease.
The local firm stands to make millions of dollars by supplying generic AIDS drugs to the whole of Africa via the PEPFAR programme.
041214
IR041244
Copyright © 2004 - Integrated Regional Information Networks (IRIN). Reproduction of this article (other than one copy for personal reference) must be cleared through the Integrated Regional Information Network. .
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980 – 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .